Septerna (NASDAQ:SEPN) Shares Down 4.4% - Time to Sell?

Septerna, Inc. (NASDAQ:SEPN - Get Free Report)'s stock price dropped 4.4% during trading on Friday . The company traded as low as $22.37 and last traded at $22.37. Approximately 17,651 shares traded hands during trading, a decline of 93% from the average daily volume of 235,892 shares. The stock had previously closed at $23.40.

Analyst Upgrades and Downgrades

SEPN has been the topic of several analyst reports. Wells Fargo & Company initiated coverage on shares of Septerna in a research note on Tuesday, November 19th. They issued an "overweight" rating and a $43.00 price objective on the stock. Cantor Fitzgerald started coverage on Septerna in a research report on Tuesday, November 19th. They issued an "overweight" rating and a $50.00 price target on the stock. TD Cowen initiated coverage on Septerna in a research report on Tuesday, November 19th. They set a "buy" rating for the company. Finally, JPMorgan Chase & Co. started coverage on Septerna in a report on Tuesday, November 19th. They issued an "overweight" rating and a $38.00 target price on the stock.

Septerna Price Performance

Insider Transactions at Septerna

In other Septerna news, major shareholder Rock Ventures V. L.P. Third purchased 370,500 shares of the business's stock in a transaction on Monday, October 28th. The shares were purchased at an average cost of $18.00 per share, for a total transaction of $6,669,000.00. Following the acquisition, the insider now owns 6,215,591 shares of the company's stock, valued at approximately $111,880,638. This represents a 6.34 % increase in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website.

Septerna Company Profile

We are a clinical-stage biotechnology company pioneering a new era of G protein-coupled receptor (GPCR) oral small molecule drug discovery powered by our proprietary Native Complex Platform™. Our industrial-scale platform aims to unlock the full potential of GPCR therapies and has led to the discovery and development of our deep pipeline of product candidates focused initially on treating patients in three therapeutic areas: endocrinology, immunology and inflammation, and metabolic diseases.